Dr Reddys Laboratories Ltd share price logo

Dr Reddys Laboratories Ltd Share Price

(DRREDDY)

₹1163.60.45%

as on 04:01PM, 17 Apr 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Dr Reddy's Laboratories Performance

  • Day's Low

    Day's High

    ₹1,150.1
    Day's Price Range
    ₹1,173.6
  • 52 Week's Low

    52 Week's High

    ₹1,020
    52-Week Price Range
    ₹1,421.49
1 Month Return-0.73 %
3 Month Return-10.65 %
1 Year Return-2.1 %
Previous Close₹1,158.40
Open₹1,150.10
Volume27.88L
Upper Circuit₹1,274.20
Lower Circuit₹1,042.60
Market Cap₹97,097.23Cr

Dr Reddy's Laboratories Fundamentals

P/E Ratio

18.04

PEG Ratio

11.07

Market Cap

₹97,097.23 Cr

P/B Ratio

4.22

EPS

66.882

Dividend Yield

0.65

Sector

Pharmaceuticals

ROE

19.42

Dr Reddy's Laboratories Analyst Rating

based on 38 analysts

HOLD

36.84%

Buy

26.32%

Hold

36.84%

Sell

Based on 38 analysts offering long term price targets for Dr Reddy's Laboratories. An average target of ₹1326.5

Source: S&P Global Market Intelligence

Dr Reddy's Laboratories Share analysis

Dr Reddy's Laboratories price forecast by 38 analysts

Upside of14.00%

High

₹1723

Target

₹1326.50

Low

₹943

Dr Reddy's Laboratories target price ₹1326.5, a slight upside of 14% compared to current price of ₹1163.6. According to 38 analysts rating.

Source: S&P Global Market Intelligence

Key events for Dr Reddys Laboratories Ltd

  • Dr Reddy's Stock Shows Modest Gains - 18 Apr, 2025

    Dr Reddy's Laboratories Ltd shares rose by 0.42% to Rs 1163, with a market capitalization of Rs 97,735 crores. The stock is fairly valued with a P/E ratio of 18, trading at a 17% discount from its 52-week high of Rs 1,420.20.
  • Dr. Reddy's Laboratories Faces Challenges Amidst Growth Plans - 16 Apr, 2025

    Dr. Reddy's Laboratories maintains a strong position in the U.S. generics market, focusing on complex generics. However, the stock has declined 8% over the past year, with unchanged EPS estimates for fiscal 2026. The company holds a Zacks Rank #3 (Hold).
  • Dr Reddy’s Shares Rise Amid Denials and Acquisitions - 15 Apr, 2025

    Dr Reddy’s Laboratories shares experienced a rise following the company's denial of workforce cut rumors and positive brokerage ratings. The company is also in discussions to acquire Sanofi's Lantus. Overall, the stock showed strong performance amid increased trading volume and positive financial indicators.
  • Dr Reddy's Denies Workforce Cost Reduction Claims - 14 Apr, 2025

    Dr Reddy's Laboratories has categorically denied media reports about a 25% workforce cost reduction, labeling them as factually incorrect. The company emphasized it does not comment on market speculations.
  • Dr Reddy's Laboratories Implements Major Downsizing - 13 Apr, 2025

    Dr Reddy's Laboratories is reducing workforce costs by 25%, potentially laying off 300-400 employees, primarily those in higher salary brackets. This move aims to offset margin pressures from declining Revlimid sales while maintaining operational efficiency and double-digit growth.
  • Dr Reddy's Faces Tax Demand of Rs 2,396 Crore - 11 Apr, 2025

    Dr Reddy's Laboratories received a show-cause notice from tax authorities demanding Rs 2,396 crore, linked to a tax issue from its 2022 merger with Dr Reddy's Holding Ltd.
  • Dr Reddy's Reports Profit Amid Stock Decline - 10 Apr, 2025

    Dr Reddy's Laboratories reported a Q3 net profit of Rs 27.9 crore, recovering from a loss last year. However, the stock fell 3.11% following the results amid broader pharma sector declines due to tariff concerns.
  • Dr Reddy's Faces Tariff Concerns Amid IT Partnership - 09 Apr, 2025

    Dr Reddy's Laboratories faces a 4% stock decline following Trump's tariff announcement on pharmaceuticals. Meanwhile, the company partners with Kyndryl to improve IT operations using AI technology.
  • Dr. Reddy's Faces Tax Notice Amid Earnings Report - 05 Apr, 2025

    Dr. Reddy's Laboratories reported a 14.7% revenue increase in Q3 FY25. The company also received a ₹2,395 crore tax reassessment notice related to a merger, asserting compliance with tax laws and plans to respond appropriately.
  • Dr Reddy's Laboratories Faces Mixed Performance - 04 Apr, 2025

    Dr Reddy's Laboratories shares have declined 19.5% YTD and 17% over six months, but long-term returns remain positive. Domestic sales are expected to grow 21% YoY, driven by the Sanofi portfolio integration, while US sales growth is projected at only 3% YoY in Q4FY25.
  • Dr Reddys Shares Surge on US Tariff Relief - 03 Apr, 2025

    On April 3, 2025, Dr Reddys Laboratories shares rose significantly as US President Trump excluded pharmaceuticals from new tariffs, leading to a 5% increase. The overall sentiment in the pharma sector was positive, with stocks opening higher and gaining throughout the day.
  • Dr Reddy's Faces Margin Pressure from Tariffs - 02 Apr, 2025

    Dr Reddy's Laboratories is likely to experience margin pressure due to potential tariff increases affecting export costs, particularly given its high reliance on the US market.
  • Concerns Over Tariffs Impacting Pharma Sector - 30 Mar, 2025

    India's 10% tariff on US pharma imports raises concerns among industry groups, highlighting potential cost burdens for distributors and generic manufacturers amid minimal US duties.
  • Dr Reddys Partners with Bio-Thera for Biosimilars - 26 Mar, 2025

    Dr Reddys Laboratories has entered into commercialization and licensing agreements with Bio-Thera Solutions for two proposed biosimilars, BAT2206 and BAT2506, targeting Southeast Asian markets and gaining exclusive rights in Colombia.
  • Dr Reddys Schedules Meeting, Completes Facility Sale - 24 Mar, 2025

    Dr Reddys Laboratories has scheduled a board meeting for May 9 to discuss financial results and dividends. Additionally, its subsidiary has finalized the sale of its Louisiana manufacturing facility.
  • Dr Reddys Sells Louisiana Subsidiary - 23 Mar, 2025

    Dr Reddys Laboratories has finalized the sale of its wholly owned subsidiary, Dr. Reddys Laboratories Louisiana LLC, including its manufacturing facility in Shreveport, Louisiana.

Insights on Dr Reddys Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 7.31K Cr → 8.53K Cr (in ₹), with an average increase of 5.0% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 1.25K Cr → 1.41K Cr (in ₹), with an average increase of 11.2% per quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 10.86% to 11.14% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 9.97% to 10.22% in Dec 2024 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 26.64% of holdings in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, DRREDDY stock has moved down by -0.7%

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 27.53% to 26.85% in Dec 2024 quarter

Dr Reddy's Laboratories News

India Revamps Gas Policy to Boost Affordability and Supply

Allocation will also now include new well gas (NWG) from nomination fields of the two state explorers, Oil and Natural Gas Corporation ONGC and Oil India OIL with auction-based allocation for new well gas being replaced with a quarterly pro-rata allocation, to ensure timely and reliable supply.18 Apr, 2025 07:16 PM

Govt Advances City Gas Allocations: CNG, PNG Get 2-Quarter Notice

The allocation will also now include gas from new wells drilled on the nomination fields of state-owned Oil and Natural Gas Corporation (ONGC) and Oil India Ltd (OIL), it added.18 Apr, 2025 06:50 PM

ONGC's APM Gas Supply Dips, Impact on City Gas Distributors

Indias top oil and gas producer ONGC has seen a drop in natural gas production from aging fields that supply CNG and piped cooking gas, resulting in supply reductions for city gas distributors like IGL, MGL, and Adani-Total, officials said. ONGC is offsetting the natural decline in output from ageing gas fields by drilling new wells. However, gas from these new wells is sold at a higher price to cover the added costs, officials said.18 Apr, 2025 04:29 PM
View More

Dr Reddy's Laboratories Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹7,214.80Cr (-)₹7,083.00Cr (↓1.83%)₹7,672.70Cr (↑8.33%)₹8,016.10Cr (↑4.48%)₹8,358.60Cr (↑4.27%)
Net Income₹1,380.90Cr (-)₹1,309.80Cr (↓5.15%)₹1,392.40Cr (↑6.31%)₹1,341.90Cr (↓3.63%)₹1,404.20Cr (↑4.64%)
Net Profit Margin19.14% (-)18.49% (↓3.40%)18.15% (↓1.84%)16.74% (↓7.77%)16.80% (↑0.36%)
Value in ₹ crore
Details2021202220232024
Total Assets₹21,956.90Cr (-)₹24,917.80Cr (↑13.49%)₹25,374.80Cr (↑1.83%)₹30,359.30Cr (↑19.64%)
Total Liabilities₹4,973.20Cr (-)₹6,581.60Cr (↑32.34%)₹4,900.60Cr (↓25.54%)₹6,118.50Cr (↑24.85%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹1,839.20Cr (-)₹3,514.20Cr (↑91.07%)₹1,338.70Cr (↓61.91%)₹5,052.90Cr (↑277.45%)₹3,449.70Cr (↓31.73%)

Dr Reddy's Laboratories Index Inclusions

Nifty Healthcare

₹13,711.05

1.16 (157.55%)

S&P BSE 100 LargeCap TMC

₹8,805.50

1.6 (138.27%)

S&P BSE Largecap

₹9,178.08

1.58 (142.8%)

Nifty100 Eq Weig

₹30,858.60

1.02 (312.45%)

BSE 100

₹24,934.68

1.55 (380.07%)

NIFTY 50

₹23,851.65

1.77 (414.45%)

S&P BSE 100 ESG

₹400.03

1.87 (7.34%)

Nifty LargeMidcap 250

₹15,053.65

1.08 (161.05%)

BSE 200

₹10,763.75

1.44 (152.51%)

S&P BSE Low Volatility

₹1,756.49

1.22 (21.19%)

Nifty100 Low Volatility 30

₹19,114.40

1.2 (225.9%)

S&P BSE Dividend Stability

₹958.58

0.75 (7.09%)

BSE Healthcare

₹41,697.12

0.91 (377.9%)

Nifty100 Quality

₹5,271.35

0.4 (21.2%)

NIFTY 100

₹24,418.35

1.59 (381.1%)

S&P BSE SENSEX 50

₹24,882.50

1.76 (429.71%)

BSE 500

₹34,109.67

1.3 (439.36%)

Nifty 500

₹21,681.55

1.3 (277.2%)

NIFTY PHARMA

₹21,126.75

1.21 (252.45%)

Nifty 200

₹13,186.10

1.42 (185.1%)

Nifty50 Value 20

₹12,362.05

1.29 (156.85%)

BSE MFG

₹971.55

0.99 (9.57%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

S&P BSE 250 LargeMidCap

₹10,181.09

1.4 (140.44%)

Dr Reddy's Laboratories Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
26.64%
0.00
Foreign Institutions
26.85%
-2.49
Mutual Funds
11.14%
2.57
Retail Investors
10.22%
2.49
Others
25.15%
0.64

Dr Reddy's Laboratories Key Indicators

Details20202021202220232024
Return On Equity %21.0811.59.1913.4619.42
Details20202021202220232024
Return On Assets %10.278.898.7617.7618.37
Details20202021202220232024
Book Value Per Share (₹)188.92214.4232.84281.07339.97
Details20202021202220232024
Earning Per Share (₹)24.3823.4626.2354.1166.88

Dr Reddy's Laboratories Valuation

Dr Reddy's Laboratories in the last 5 years

  • Overview

  • Trends

Lowest (3.37x)

October 27, 2019

Today (18.04x)

April 17, 2025

Industry (53.02x)

April 17, 2025

Highest (53.88x)

December 18, 2020

LowHigh

Dr Reddy's Laboratories Earnings and Dividends

  • Dr Reddys Laboratories Ltd Earnings Results

    Dr Reddys Laboratories Ltd’s net profit jumped 2.38% since last year same period to ₹1,413.70Cr in the Q3 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated 12.58% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Dr Reddys Laboratories Ltd Dividends May,2024

    In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 6.88%.

    Read More about Dividends

Dr Reddy's Laboratories Technicals Summary

Bearish

Neutral

Bullish

Bullish

Dr Reddys Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.

Dr Reddy's Laboratories Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
HOLD₹97,097.23 Cr10.26%0.52₹5,577 Cr₹28,011 Cr
HOLD₹1,49,724.28 Cr28.15%0.50₹1,600 Cr₹7,845 Cr
BUY₹1,10,152.27 Cr35.85%0.67₹1,656 Cr₹10,727 Cr
BUY₹39,775.88 Cr-1.49%0.58₹1,297 Cr₹14,755 Cr
HOLD₹23,879.80 Cr-4.07%0.50₹772 Cr₹5,664 Cr

About Dr Reddy's Laboratories

Dr Reddy's Laboratories Ltd was founded in 1984 and is based in Hyderabad, India. It is a pharmaceutical company that is listed on the Bombay Stock Exchange and National Stock Exchange of India. It has operations in over 60 countries and offers a wide range of products and services in the pharmaceuticals and healthcare sectors. The company has a strong focus on research and development and has over 6,000 employees worldwide.

Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.

Revenue: ₹8,358.60Cr as on December 2024 (Q4 24)
Net Profit: ₹1,404.20Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
OrganisationDr Reddy's Laboratories
HeadquartersHyderabad
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Dr Reddys Laboratories Ltd

What is Dr Reddys Laboratories Ltd price today?

Dr Reddys Laboratories Ltd share price today stands at ₹1163.6, Open: ₹1150.1, Previous Close: ₹1158.4, High: ₹1173.6, Low: ₹1150.1, 52 Week High: ₹1421.49, 52 Week Low: ₹1020.

How to Buy Dr Reddys Laboratories Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Dr Reddys Laboratories Ltd shares

What are today's traded volumes of Dr Reddys Laboratories Ltd?

Today's traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 27.88L.

What is today's market capitalisation of Dr Reddys Laboratories Ltd?

Today's market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹97097.23Cr.

What is the 52 Week High and Low Range of Dr Reddys Laboratories Ltd?

Dr Reddys Laboratories Ltd (DRREDDY)
Price
52 Week High
₹1421.49
52 Week Low
₹1020

How much percentage Dr Reddys Laboratories Ltd is down from its 52 Week High?

Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1163.6. It is down -18.14% from its 52 Week High price of ₹1421.49

How much percentage Dr Reddys Laboratories Ltd is up from its 52 Week low?

Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1163.6. It is up 14.08% from its 52 Week Low price of ₹1020